Based on the results shown here, our prediction is that PI3K, panAKT or specific AKT1 inhibition may not be recommended, and may even be contraindicated in breast cancer, as it might promote tumor invasiveness and cancer dissemination. Here, PIK3CA is linked to neoplasm.